215 related articles for article (PubMed ID: 34409252)
1. Hypoxia-Related Radiomics and Immunotherapy Response: A Multicohort Study of Non-Small Cell Lung Cancer.
Tunali I; Tan Y; Gray JE; Katsoulakis E; Eschrich SA; Saller J; Aerts HJWL; Boyle T; Qi J; Guvenis A; Gillies RJ; Schabath MB
JNCI Cancer Spectr; 2021 Aug; 5(4):. PubMed ID: 34409252
[TBL] [Abstract][Full Text] [Related]
2. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
3. A novel sub-regional radiomics model to predict immunotherapy response in non-small cell lung carcinoma.
Peng J; Zou D; Zhang X; Ma H; Han L; Yao B
J Transl Med; 2024 Jan; 22(1):87. PubMed ID: 38254087
[TBL] [Abstract][Full Text] [Related]
4. Combination of computed tomography imaging-based radiomics and clinicopathological characteristics for predicting the clinical benefits of immune checkpoint inhibitors in lung cancer.
Yang B; Zhou L; Zhong J; Lv T; Li A; Ma L; Zhong J; Yin S; Huang L; Zhou C; Li X; Ge YQ; Tao X; Zhang L; Son Y; Lu G
Respir Res; 2021 Jun; 22(1):189. PubMed ID: 34183009
[TBL] [Abstract][Full Text] [Related]
5. Novel, non-invasive imaging approach to identify patients with advanced non-small cell lung cancer at risk of hyperprogressive disease with immune checkpoint blockade.
Vaidya P; Bera K; Patil PD; Gupta A; Jain P; Alilou M; Khorrami M; Velcheti V; Madabhushi A
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33051342
[TBL] [Abstract][Full Text] [Related]
6. Radiomics of
Mu W; Tunali I; Gray JE; Qi J; Schabath MB; Gillies RJ
Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1168-1182. PubMed ID: 31807885
[TBL] [Abstract][Full Text] [Related]
7. Changes in CT Radiomic Features Associated with Lymphocyte Distribution Predict Overall Survival and Response to Immunotherapy in Non-Small Cell Lung Cancer.
Khorrami M; Prasanna P; Gupta A; Patil P; Velu PD; Thawani R; Corredor G; Alilou M; Bera K; Fu P; Feldman M; Velcheti V; Madabhushi A
Cancer Immunol Res; 2020 Jan; 8(1):108-119. PubMed ID: 31719058
[TBL] [Abstract][Full Text] [Related]
8. Development and validation of an MRI-Based nomogram to predict the effectiveness of immunotherapy for brain metastasis in patients with non-small cell lung cancer.
Xu J; Wang P; Li Y; Shi X; Yin T; Yu J; Teng F
Front Immunol; 2024; 15():1373330. PubMed ID: 38686383
[TBL] [Abstract][Full Text] [Related]
9. Preoperative CT-based radiomic prognostic index to predict the benefit of postoperative radiotherapy in patients with non-small cell lung cancer: a multicenter study.
Ma Z; Men Y; Liu Y; Bao Y; Liu Q; Yang X; Wang J; Deng L; Zhai Y; Bi N; Wang L; Hui Z
Cancer Imaging; 2024 May; 24(1):61. PubMed ID: 38741207
[TBL] [Abstract][Full Text] [Related]
10. Development and validation of a genomic mutation signature to predict response to PD-1 inhibitors in non-squamous NSCLC: a multicohort study.
Bai X; Wu DH; Ma SC; Wang J; Tang XR; Kang S; Fu QJ; Cao CH; Luo HS; Chen YH; Zhu HB; Yan HH; Wu YL; Dong ZY
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32606052
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.
Zhu J; Li R; Tiselius E; Roudi R; Teghararian O; Suo C; Song H
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011300. PubMed ID: 29247502
[TBL] [Abstract][Full Text] [Related]
12. CT imaging features associated with recurrence in non-small cell lung cancer patients after stereotactic body radiotherapy.
Li Q; Kim J; Balagurunathan Y; Qi J; Liu Y; Latifi K; Moros EG; Schabath MB; Ye Z; Gillies RJ; Dilling TJ
Radiat Oncol; 2017 Sep; 12(1):158. PubMed ID: 28946909
[TBL] [Abstract][Full Text] [Related]
13. Predictive value of tumor mutational burden for immunotherapy in non-small cell lung cancer: A systematic review and meta-analysis.
Meng G; Liu X; Ma T; Lv D; Sun G
PLoS One; 2022; 17(2):e0263629. PubMed ID: 35113949
[TBL] [Abstract][Full Text] [Related]
14. Radiomics study for predicting the expression of PD-L1 in non-small cell lung cancer based on CT images and clinicopathologic features.
Sun Z; Hu S; Ge Y; Wang J; Duan S; Song J; Hu C; Li Y
J Xray Sci Technol; 2020; 28(3):449-459. PubMed ID: 32176676
[TBL] [Abstract][Full Text] [Related]
15. Combined Immunotherapy and Stereotactic Radiotherapy Improves Neurologic Outcomes in Patients with Non-small-cell Lung Cancer Brain Metastases.
Enright TL; Witt JS; Burr AR; Yadav P; Leal T; Baschnagel AM
Clin Lung Cancer; 2021 Mar; 22(2):110-119. PubMed ID: 33281062
[TBL] [Abstract][Full Text] [Related]
16. Circulating miRNAs and PD-L1 Tumor Expression Are Associated with Survival in Advanced NSCLC Patients Treated with Immunotherapy: a Prospective Study.
Boeri M; Milione M; Proto C; Signorelli D; Lo Russo G; Galeone C; Verri C; Mensah M; Centonze G; Martinetti A; Sottotetti E; Pastorino U; Garassino MC; Sozzi G
Clin Cancer Res; 2019 Apr; 25(7):2166-2173. PubMed ID: 30617131
[TBL] [Abstract][Full Text] [Related]
17. CT derived radiomic score for predicting the added benefit of adjuvant chemotherapy following surgery in stage I, II resectable non-small cell lung cancer: a retrospective multicohort study for outcome prediction.
Vaidya P; Bera K; Gupta A; Wang X; Corredor G; Fu P; Beig N; Prasanna P; Patil PD; Velu PD; Rajiah P; Gilkeson R; Feldman MD; Choi H; Velcheti V; Madabhushi A
Lancet Digit Health; 2020 Mar; 2(3):e116-e128. PubMed ID: 33334576
[TBL] [Abstract][Full Text] [Related]
18. [18F]FDG PET immunotherapy radiomics signature (iRADIOMICS) predicts response of non-small-cell lung cancer patients treated with pembrolizumab.
Valentinuzzi D; Vrankar M; Boc N; Ahac V; Zupancic Z; Unk M; Skalic K; Zagar I; Studen A; Simoncic U; Eickhoff J; Jeraj R
Radiol Oncol; 2020 Jul; 54(3):285-294. PubMed ID: 32726293
[TBL] [Abstract][Full Text] [Related]
19. Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non-small cell lung cancer treated with first-line pembrolizumab.
Dall'Olio FG; Calabrò D; Conci N; Argalia G; Marchese PV; Fabbri F; Fragomeno B; Ricci D; Fanti S; Ambrosini V; Ardizzoni A
Eur J Cancer; 2021 Jun; 150():99-107. PubMed ID: 33892411
[TBL] [Abstract][Full Text] [Related]
20. A short-term follow-up CT based radiomics approach to predict response to immunotherapy in advanced non-small-cell lung cancer.
Gong J; Bao X; Wang T; Liu J; Peng W; Shi J; Wu F; Gu Y
Oncoimmunology; 2022; 11(1):2028962. PubMed ID: 35096486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
